Business Context and Reporting Period
This Form 8-K filing by Tempus AI, Inc. (TEM) reports a current event dated August 16, 2024. The filing details a strategic investment and commercial agreement with Personalis, Inc., a genomic testing company.
Key Financial Metrics and Transaction Details
The filing discloses specific capital outflows related to the acquisition of equity and the exercise of warrants in Personalis, Inc.:
- Direct Equity Purchase: Tempus purchased 3,500,000 shares of Personalis common stock at $5.07 per share, totaling $17,745,000.
- Warrant Exercise: Tempus exercised two existing warrants to purchase an aggregate of 9,218,800 shares at exercise prices of $1.50 and $2.50, totaling $18,437,600.
- Total Cash Outflow: The combined transaction resulted in a total payment of $36,182,600 to Personalis.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for Tempus AI's revenue, profit, cash flow, or margins for the reporting period.
- Debt and Liquidity: The filing text does not provide a clear value for Tempus AI's debt levels or overall liquidity position.
Material Changes and Commercial Agreement Amendments
Beyond the financial transaction, the filing reports material changes to the Commercialization and Reference Laboratory Agreement between Tempus and Personalis:
- Termination Notice Period: Extended from the prior term to 30 months for termination for convenience.
- Competitor Protections: Added obligations for Personalis regarding assignments to competitors or change of control transactions involving competitors.
- Capacity Commitments: Increased the number of new patients for which Personalis commits to maintaining laboratory capacity under certain circumstances.
- Registration Rights: Personalis agreed to file a registration statement for the resale of the newly purchased shares within 30 calendar days.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking revenue projections, or management commentary regarding Tempus AI's general business outlook. The primary focus is the execution of the investment agreement. No specific risks or contingencies beyond the standard terms of the commercial agreement amendment are detailed in this text.
Key Facts for Investor Verification
- Verify the total cash impact of $36.18 million on Tempus AI's current liquidity and cash reserves.
- Confirm the total ownership stake Tempus AI now holds in Personalis, Inc. following the purchase of 3.5M shares and the exercise of warrants for 9.2M shares.
- Review the specific terms of the 30-month termination notice to understand the long-term lock-in of the commercial relationship.
- Monitor the filing of the registration statement by Personalis within the required 30-day window to ensure liquidity for the shares held by Tempus.